HLA-G in Preeclampsia: a Pilot Study to Propose a Tolerogenic Treatment
Background: The serum level of soluble Human Leukocyte Antigen-antigen-D Related (HLA)-(DR) (sHLA-DR) may appear as a useful parameter to monitor maternal immune response during pregnancy. Objective: The aim was to compare HLA-G serum levels in patients with or without preeclampsia.
Methods: Pregnant women seen at the “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital (HMPMPS) were recruited at their first visit. Two groups were conformed: a) women with healthy pregnancies, and b) women with preeclampsia. The patients’ sociodemographic and laboratory data were introduced into the SPSS software program. HLA-G quantification was performed in peripheral blood samples through the Enzyme-linked Immunosorbent Assay (ELISA) method.
Results: The total number of women seen was 16 (mean age, 24 ± 8 years), eight healthy women (mean age, 22 ± 3 years) and eight women with preeclampsia (mean age, 27 ± 7 years). Women with preeclampsia were older, heavier, had higher levels of Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP), and referred less sexual intercourse per week than healthy pregnant women. There was no difference in HLA-G levels.
Conclusion: The sexual intercourse frequency is a major factor to develop preeclampsia and the serum HLA-G levels measured previous to the child delivery or cesarean are not different between women with or without preeclampsia.
Velasco-Murillo V, Navarrete-Hernández E. [Maternal mortality in the IMSS: an analysis from the perspective of mortality and lethality]. Cir Cir 2006 Jan-Feb;74:21–6. spanish
Dekker GA, Sibai BM. The immunology of preeclampsia. Semin Perinatol 1999 Feb;23:24–33.
Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD, et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol 2003 Jun;157:1108–14.
Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol 1994 Jun;8:443–68.
Paller MS. Hypertension in pregnancy. J Am Soc Nephrol 1998 Feb;9:314–21.
Mendieta Zerón H1, García Solorio VJ, Nava Díaz PM, Garduño Alanís A, Santillán Benítez JG, Domínguez García V, et al. Hyperleptinemia as a prognostic factor for preeclampsia: a cohort study. Acta Medica (Hradec Kralove) 2012;55:165–171.
Muñoz-Suano A, Hamilton AB, Betz AG. Gimme shelter: the immune system during pregnancy. Immunol Rev 2011 May;241:20–38.
Sado T, Naruse K, Noguchi T, et al. Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res 2011 Jun;60:509–20.
Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J 2008 Jan; 27:1–5.
Tilburgs T, Scherjon SA, Claas FHJ. Major histocompatibility complex (MHC)-mediated immune regulation of decidual leukocytes at the fetal-maternal interface. J Reprod Immunol 2010 May;85:58–62.
Roussev RG, Coulam CB. HLA-G and its role in implantation (review). J.Assist. Reprod. Genet. 2007 Jul;24:288–295.
Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum. Reprod. Update 2006 May-Jun;12:209–232.
Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A. Inadequate tolerance induction may induce pre-eclampsia. J Reprod Immunol 2007 Dec;76:30–9.
ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002 Apr;77:67-75.
Saftlas AF, Rubenstein L, Prater K, Harland KK, Field E, Triche E. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol 2014 Mar;101-102:104–110.
Olayemi O, Strobino D, Aimakhu C, Adedapo K, Kehinde A, Odukogbe AT, et al. Influence of duration of sexual cohabitation on the risk of hypertension in nulliparous parturients in Ibadan: A cohort study. Aust N Z J Obstet Gynaecol 2010 Feb;50:40–4.
Kho EM, McCowan LME, North RA, Roberts CT, Chan E, Black MA, et al. Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol 2009 Oct;82:66–73.
Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Gonçalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol 2004 Jun;190:1541–7.
Rizzo R, Andersen AS, Lassen MR, Sørensen HC, Bergholt T, Larsen MH, et al. Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. Am J Reprod Immunol 2009 Nov;62:320–38.
Yie S, Li L, Li Y, Librach C. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am J Obstet Gynecol 2004 Aug;191:525–9.
Steinborn A, Varkonyi T, Scharf A, Bahlmann F, Klee A, Sohn C. Early detection of decreased soluble HLA-G levels in the maternal circulation predicts the occurrence of preeclampsia and intrauterine growth retardation during further course of pregnancy. Am J Reprod Immunol 2007 Apr;57:277–86.
Yie S, Taylor RN, Librach C. Low plasma HLA-G protein concentrations in early gestation indicate the development of preeclampsia later in pregnancy. Am J Obstet Gynecol 2005 Jul;193:204–8.
Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE. Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia. Am J Obstet Gynecol 2007 Sep;197:255.e1–5.
Vercammen MJ, Verloes A, Van de Velde H, Haentjens P. Accuracy of soluble human leukocyte antigen-G for predicting pregnancy among women undergoing infertility treatment: meta-analysis. Hum Reprod Update 2008 May-Jun; 14:209–218.
Kotze D, Kruger TF, Lombard C, et al. The effect of the biochemical marker soluble human leukocyte antigen G on pregnancy outcome in assisted reproductive technology--a multicenter study. Fertil Steril 2013 Nov;100:1303–9.
Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens 69 Suppl 2007 Apr;1:140–142.
Wu FX, Wu LJ, Luo XY, Tang Z, Yang MH, Xie CM, et al. Lack of association between HLA-G 14-bp polymorphism and systemic lupus erythematosus in a Han Chinese population. Lupus 2009 Dec;18:1259–66.
Zheng XQ, Li CC, Xu DP, Lin A, Bao WG, Yang GS, Yan WH. Analysis of the plasma soluble human leukocyte antigen-G and interleukin-10 levels in childhood atopic asthma. Hum Immunol 2010 Oct;71:982–7.
Bıyık I. Maternal serum soluble HLA-G in complicated pregnancies. J Matern Fetal Neonatal Med. 2014 Mar;27:381-4.
O'Brien M, McCarthy T, Jenkins D, Paul P, Dausset J, Carosella ED, et al. Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. Cell Mol Life Sci. 2001 Nov;58:1943-9.
Darmochwal-Kolarz D, Kolarz B, Rolinski J, Leszczynska-Gorzelak B, Oleszczuk J. The concentrations of soluble HLA-G protein are elevated during mid-gestation and decreased in pre-eclampsia. Folia Histochem Cytobiol. 2012 Jul;50:286-91.
Dahl M, Klitkou L, Christiansen OB, Djurisic S, Piosik ZM, Skovbo P, et al. Human leukocyte antigen (HLA)-G during pregnancy part II: associations between maternal and fetal HLA-G genotypes and soluble HLA-G. Hum Immunol. 2015 Apr;76:260-71.
Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR. Polymorphism in the 5′ Upstream Regulatory and 3′ Untranslated Regions of the HLA-G Gene in Relation to Soluble HLA-G and IL-10 Expression. Hum Immunol. 2006 Jan-Feb;67:53–62.
Rizzo R, Hviid TV, Govoni M, Padovan M, Rubini M, Melchiorri L, et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens 2008 Jun; 71:520–9.
Twito T, Joseph J, Mociornita A, Rao V, Ross H, Delgado DH. The 14-bp deletion in the HLA-G gene indicates a low risk for acute cellular rejection in heart transplant recipients. J Heart Lung Transplant 2011 Jul;30:778–82.
Chen XY, Yan WH, Lin A, Xu HH, Zhang JG, Wang XX. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 2008 Oct;72:335–41.
Dahl M, Perin TL, Djurisic S, Rasmussen M, Ohlsson J, Buus S, et al. Soluble human leukocyte antigen-G in seminal plasma is associated with HLA-G genotype: possible implications for fertility success. Am J Reprod Immunol 2014 Jul;72:89–105.
Dahl M, Djurisic S, Hviid TVF. The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy. J Immunol Res 2014;2014:591489.
Rao RS, Kumar CG, Prakasham RS, Hobbs PJ. The Taguchi methodology as a statistical tool for biotechnological applications: a critical appraisal. Biotechnol J. 2008 Apr;3:510-23.
Copyright (c) 2018 César Lucio García, Cynthia Ayerim Lucio García, Arely Sarai Alonso Barreto, María del Socorro Camarillo Romero, Cristian Fabian Layton Tovar, Deisy Julieth Abril Riaño, Hugo Mendieta Zerón
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to firstname.lastname@example.org
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to email@example.com